Diversity of approaches to classic galactosemia around the world: a comparison of diagnosis, intervention, and outcomes

• Type of Material: Article
• Authors: Patricia P. Jumbo-Lucioni, Emory University; Kathryn Garber, Emory University; John Kiel, Emory University; Ivo Baric, University Hospital Center, Zagreb; Gerard T. Berry, Harvard University; Annet Bosch, University of Amsterdam; Alberto Burlina, University of Padova; Ana Chiesa, Hospital de Niños “Ricardo Gutiérrez”; Maria Luz Couce Pico, Hospital Clínico Universitario; Sylvia C. Estrada, University of the Philippines; Howard Henderson, University of Cape Town; Nancy Leslie, University of Cincinnati; Nicola Longo, University of Utah; Andrew A. M. Morris, Royal Manchester Children’s Hospital; Carlett Ramirez-Farias, Ministry of Health, Mexico City; Susanne Schweitzer-Krantz, Evangelisches Krankenhaus; Catherine Lynn T. Silao, University of the Philippines Manila; Marcela Vela-Amieva, Ministry of Health, Mexico City; Susan Waisbren, Harvard University; Judith L. Fridovich-Keil, Emory University
• Language: English
• Date: 2012-11
• Publisher: Springer Verlag (Germany)
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © SSIEM and Springer 2012
• Final Published Version (URL): http://link.springer.com/article/10.1007%2Fs10545-012-9477-y
• Title of Journal or Parent Work: Journal of Inherited Metabolic Disease
• ISSN: 0141-8955
• Volume: 35
• Issue: 6
• Start Page: 1037
• End Page: 1049
• Grant/Funding Information: This work was supported by the National Institutes of Health grant R01 DK059904 (to JLFK).
• Research Categories: Biology, Genetics

Abstract

Without intervention, classic galactosemia is a potentially fatal disorder in infancy. With the benefit of early diagnosis and dietary restriction of galactose, the acute sequelae of classic galactosemia can be prevented or reversed. However, despite early and lifelong dietary treatment, many galactosemic patients go on to experience serious long-term complications including cognitive disability, speech problems, neurological and/or movement disorders and, in girls and women, ovarian dysfunction. Further, there remains uncertainty surrounding what constitutes a ‘best practice’ for treating this disorder. To explore the extent and implications of this uncertainty, we conducted a small but global survey of healthcare providers who follow patients with classic galactosemia, seeking to compare established protocols for diagnosis, intervention, and follow-up, as well as the outcomes and outcome frequencies seen in the patient populations cared for by these providers. We received 13 survey responses representing five continents and 11 countries. Respondents underscored disparities in approaches to diagnosis, management and follow-up care. Notably, we saw no clear relationship between differing approaches to care and long-term outcomes in the populations studied. Negative outcomes occurred in the majority of cases regardless of when treatment was initiated, how tightly galactose intake was restricted, or how closely patients were monitored. We document here what is, to our knowledge, the first global comparison of healthcare approaches to classic galactosemia. These data reinforce the idea that there is currently no one best practice for treating patients with classic galactosemia, and underscore the need for more extensive and statistically powerful comparative studies to reveal potential positive or negative impacts of differing approaches.